GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tsubota Laboratory Inc (TSE:4890) » Definitions » Cash, Cash Equivalents, Marketable Securities

Tsubota Laboratory (TSE:4890) Cash, Cash Equivalents, Marketable Securities : 円1,509.0 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Tsubota Laboratory Cash, Cash Equivalents, Marketable Securities?

Tsubota Laboratory's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 (円1,860.45 Mil) to Sep. 2023 (円1,643.23 Mil) but then stayed the same from Sep. 2023 (円1,643.23 Mil) to Dec. 2023 (円1,509.05 Mil).

Tsubota Laboratory's annual cash, cash equivalents, marketable securities increased from Mar. 2022 (円1,174.93 Mil) to Mar. 2023 (円2,161.02 Mil) but then declined from Mar. 2023 (円2,161.02 Mil) to Mar. 2024 (円1,883.40 Mil).


Tsubota Laboratory Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Tsubota Laboratory's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tsubota Laboratory Cash, Cash Equivalents, Marketable Securities Chart

Tsubota Laboratory Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Cash, Cash Equivalents, Marketable Securities
380.68 610.77 1,174.93 2,161.02 1,883.40

Tsubota Laboratory Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,161.02 1,860.45 1,643.23 1,509.05 1,883.40

Tsubota Laboratory Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Tsubota Laboratory  (TSE:4890) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Tsubota Laboratory Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Tsubota Laboratory's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Tsubota Laboratory (TSE:4890) Business Description

Industry
Traded in Other Exchanges
N/A
Address
34 Shinanomachi, 304 Toshin Shinanomachi-ekimae Building, Shinjuku-ku, Tokyo, JPN, 160-0016
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.

Tsubota Laboratory (TSE:4890) Headlines

No Headlines